+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma



Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma



Current Drug Safety 8(2): 148-152



There is increasing evidence that tyrosine kinase inhibitors (TKIs) have significant blood glucose lowering effects. A 70-year old Caucasian male with liver cirrhosis Child-Pugh A, advanced hepatocellular carcinoma and diabetes had a stable glycemic control being treated with glibenclamide (3.5 mg twice daily). After the first daily dose of the TKI sorafenib (800 mg) the patient experienced acute nocturnal disorientation and somnolence with a corresponding blood glucose of 37 mg/dl. After administration of glucose intravenously the neurological disturbances were completely reversible. As there was no intercurrent deterioration neither of hepatic nor of renal function, the severe hypoglycemia can likely be attributed to a drug-drug interaction of sorafenib with the sulfonylurea. The complete inhibition of the CYP2C9 and CYP3A4 mediated metabolic pathway of glibenclamide through sorafenib might have resulted in a rapid accumulation of glibenclamide. Profound blood glucose lowering effects of sorafenib might have additionally contributed to the hypoglycemic episode.

(PDF emailed within 1 workday: $29.90)

Accession: 055739578

Download citation: RISBibTeXText

PMID: 23845193


Related references

Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma. 2013

Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Cancer ChemoTherapy and Pharmacology 72(1): 269-272, 2013

Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Investigational New Drugs 29(6): 1511-1514, 2012

SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model. Molecular Cancer Therapeutics 13(1): 27-36, 2014

Sorafenib-induced severe urticaria in a patient with hepatocellular cancer. Journal of Oncology Pharmacy Practice 22(2): 350-353, 2015

Sorafenib combined with radiofrequency ablation in the treatment of a patient with renal cell carcinoma plus primary hepatocellular carcinoma. Journal of Cancer Research and Therapeutics 11(4): 1026-1026, 2016

A case of severe acalculous cholecystitis associated with sorafenib treatment for advanced hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 4(5): 115-118, 2012

Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma. Journal of Drugs in Dermatology 13(8): 899-900, 2016

Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. World Journal of Gastroenterology 17(2): 267-270, 2011

Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma. Digestive and Liver Disease 43(4): 333-334, 2011

Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib. Isrn Gastroenterology 2011: 201529-201529, 2011

Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array. International Journal of Clinical and Experimental Pathology 8(3): 3027-3035, 2016

Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 35(3): 234-236, 2011

Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World Journal of Gastroenterology 20(39): 14505-9, 2015

Remission of Psoriasis in a Patient with Hepatocellular Carcinoma Treated with Sorafenib. In Vivo 30(5): 677-680, 2016